The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Male or female subjects ≥18 years of age.
Histologically or cytologically confirmed SCLC.
Subjects who progressed on or after first-line platinum-based regimens.
Has at least 1 measurable lesion as defined per RECIST 1.1.
Combined SCLC, any previous diagnosis of transformed SCLC or SCLC that has transformed to NSCLC.
Chemotherapy-free interval ≤30 days.
Has received prior treatment with anti-B7 homologue 3 (B7-H3) targeted agents.
Has received prior treatment with topoisomerase I inhibitor, including ADC that consists of topoisomerase I inhibitor.